Johnson & Johnson's two-dose vaccine regimen against Ebola is safe and produces a strong immune response in people 1 year old and older, according to two studies published this week in The Lancet Infectious Diseases.The studies detailed the results of phase 2 randomized, controlled trials in Sierra Leone, which is one of the three countries that was hit hard during the massive 2014-16 West African Ebola outbreak.A potentially easier supply chainJohnson & Johnson's vaccine regimen consists of a dose of the adenovirus vector-based vaccine Ad26.ZEBOV followed 8 weeks later by a different vector-based vaccine called the MVA-BN-Filo.Because of these results, Johnson & Johnson received approval and marketing authorization from the European